BeiGene: Clinical Trials

24 trials sponsored by BeiGene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 5 terminated, 4 active not recruiting, 2 recruiting. 24 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 324Completed 12, Terminated 5, Active not recruiting 4, Recruiting 2, Withdrawn 1

Follow BeiGene: new trials by email

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Tislelizumab, Blood sampling, Placebo - Cancer, Lung Cancer
Phase 3RecruitingGustave Roussy, Cancer Campus, Grand Paris7172025-04-162025-05-13
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
Tislelizumab, Adjuvant chemotherapy - Colorectal Cancer, Microsatellite Instability High
Phase 3RecruitingSun Yat-sen University1802024-11-012024-11-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma
Phase 3WithdrawnBeiGene2023-06-302023-06-07
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Tislelizumab, Docetaxel, Sitravatinib - Non-Small Cell Lung Cancer (NSCLC)
Phase 3TerminatedBeiGene3772021-07-272025-06-29
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
Tislelizumab, Durvalumab, Ociperlimab - Non Small Cell Lung Cancer
Phase 3TerminatedBeiGene632021-06-172024-10-31
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Tislelizumab, Ociperlimab, Pembrolizumab - Non-small Cell Lung Cancer, NSCLC
Phase 3TerminatedBeiGene6692021-05-242026-05-12
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Tislelizumab, Salvage Chemotherapy - Classical Hodgkin Lymphoma
Phase 3TerminatedBeiGene32020-12-142026-03-02
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Tislelizumab, Cisplatin injection, Paclitaxel injection - Non Small Cell Lung Cancer
Phase 3Active not recruitingBeiGene4532020-05-292026-03-18
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Tislelizumab, Cisplatin, Carboplatin - Small Cell Lung Cancer
Phase 3CompletedBeiGene4572019-07-222025-02-28
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Tislelizumab, Placebo, Paclitaxel - Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3CompletedBeiGene3702019-06-112026-04-13
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Tislelizumab, Placebo, Cisplatin - Urothelial Carcinoma
Phase 3Active not recruitingBeiGene4202019-05-292026-06-22
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo - Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedCelgene12019-05-222020-07-15
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
Tislelizumab, Placebo, Gemcitabine - Recurrent or Metastatic Nasopharyngeal Cancer
Phase 3CompletedBeiGene2632019-03-272025-01-31
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Tislelizumab, Placebo, Cisplatin - Gastric, or Gastroesophageal Junction Adenocarcinoma
Phase 3CompletedBeiGene9972018-12-132025-02-14
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Cisplatin, Oxaliplatin, Fluorouracil (5-FU) - Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3CompletedBeiGene6492018-12-112025-07-29
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Zanubrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3CompletedBeiGene6522018-11-012025-03-30
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Tislelizumab, Paclitaxel, Nab-paclitaxel - Non-Small Cell Lung Cancer
Phase 3CompletedBeiGene3602018-07-302024-10-26
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
Tislelizumab, Cisplatin, Carboplatin - Non-Small Cell Lung Cancer
Phase 3CompletedBeiGene3342018-07-232025-02-04
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Pamiparib capsule, Placebo capsule - Ovarian Cancer
Phase 3Active not recruitingBeiGene2242018-05-142026-03-16
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Tislelizumab, Paclitaxel, Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3CompletedBeiGene5122018-01-262024-10-26

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (8)  ·  Esophageal Squamous Cell Carcinoma (3)  ·  Carcinoma, Hepatocellular (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Neoplasm Metastasis (2)  ·  Recurrence (2)  ·  Carcinoma, Transitional Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Sarcoma (1)

Interventions

tislelizumab (20)  ·  Cisplatin (8)  ·  Carboplatin (5)  ·  Paclitaxel (5)  ·  Docetaxel (3)  ·  zanubrutinib (3)  ·  Capecitabine (2)  ·  Chemoradiotherapy (2)  ·  Fluorouracil (2)  ·  Gemcitabine (2)  ·  Oxaliplatin (2)  ·  Pemetrexed (2)  ·  Radiotherapy (2)  ·  ibrutinib (2)  ·  sitravatinib (2)

Countries

China (21)  ·  France (10)  ·  Spain (10)  ·  Taiwan (10)  ·  United States (10)  ·  Italy (9)  ·  Poland (9)  ·  United Kingdom (8)  ·  Australia (7)  ·  Germany (7)  ·  Japan (6)  ·  Russia (6)  ·  Belgium (5)  ·  Czechia (5)  ·  South Korea (5)

Top investigators

Caicun Zhou, PhD (1)  ·  Dingwei Ye, MD (1)  ·  Jin Wang, MD (1)  ·  Marie Nguyen, MD (1)  ·  Pei-Rong Ding, M.D. (1)  ·  Weihu Wang, MD (1)  ·  Xia Zhao, MD (1)  ·  Zefen Xiao, MD (1)

Results publications

PMID 38502198, PMID 40373876, PMID 29869556, PMID 30969136, PMID 31875923, PMID 32207333, PMID 33054121, PMID 33509647, PMID 34033975, PMID 34269067, PMID 35333492, PMID 35442766, PMID 35785595, PMID 35810754, PMID 36184068, PMID 37080222, PMID 37207654, PMID 37478390, PMID 37587845, PMID 37752878, PMID 37752892, PMID 37796513, PMID 37846080, PMID 38052215, PMID 38088119, PMID 38240916, PMID 38305608, PMID 38414510, PMID 38460751, PMID 38598745, PMID 38671587, PMID 38806195, PMID 38888616, PMID 38923910, PMID 39072392, PMID 39316666, PMID 39435268, PMID 39482589, PMID 39581197, PMID 39626287, PMID 39647999, PMID 39738721, PMID 39853273, PMID 40075024, PMID 40075025, PMID 40179324, PMID 40448577, PMID 40528576, PMID 40924923, PMID 40944848

NIH funding

2018 (5), 2017 (3), 2023 (2), 2016 (1)